ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1491

Clinically Relevant Differences in the Mobility of Patients with Axial Spondyloarthritis Related to Daytime of Performance

David Kiefer1, Juergen Braun1, Lucia Schneider1, Niklas Kolle1, Uta Kiltz1, Ioana Andreica2, Philipp Sewerin1, Bjoern Buehring3, susanne herbold1 and Xenofon Baraliakos4, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, 3Bergisches Rheuma-Zentrum, Velbert, Germany, 4Rheumazentrum Ruhrgebiet Herne, Herne, Germany

Meeting: ACR Convergence 2022

Keywords: Morning Stiffness, Outcome measures, physical examination, physical function, spondyloarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Patients with axial spondyloarthritis (axSpA) often experience impairments of spinal mobility and physical function due to inflammation and structural damage. Back pain and morning stiffness are common symptoms and part of established disease activity criteria but are not included in mobility assessments. The diurnal rhythm of proinflammatory cytokines and cortisol is known to peak in the early morning hours. This study objective is to compare the performance of patients with axSpA regarding measures of mobility and physical function including objective electronic measurements with the Epionics SPINE device (ES) at different times of the day.

Methods: Consecutive inpatients with axSpA were examined once in the morning (V1: before 10:00am) and once in the afternoon (V2: after 02:00pm) by the Bath AS spinal mobility score (BASMI), the AS physical performance index (ASPI), the Short Physical Performance Battery (SPPB) and measurements with the ES, including range of motion (RoM) and kinematics (RoK). The results were compared using t-tests. Medication with NSAIDs and biologics was recorded.

Results: A total of 101 patients with axSpA (64 r-axSpA; 37 nr-axSpA) were included (Table 1). Significant differences between assessments performed in the morning vs. the afternoon were seen for ASPI, and SPPB, and for ES measures of speed (RoK; p< 0.018) but not for RoM, except for lateral flexion (p=0.002) (Table 2 and 3). Total BASMI scores slightly improved but single BASMI items showed variability (Table 2). Differences between nr-axSpA and r-axSpA were observed in age, sex, spinal mobility, CRP and percentage of HLA B27-positivity but not for disease activity and function (table 1).

Conclusion: Spinal mobility of patients with axSpA differs considerably at different times of the day, being worse in the morning and improving significantly in the afternoon. Importantly, this was most prominently shown by performance-based measures in comparison to standard assessments such as BASMI. Data on diurnal variation of mobility has important implications for clinical studies, strongly suggesting that the daytime of assessments needs to be standardized. Whether and how medication has an influence on this remains to be evaluated.

Supporting image 1

*variables are mean ± standard deviation if not otherwise indicated; BASMI: Bath Ankylosing Spondylitis (AS) Metrology Index; BASDAI: Bath AS Disease Activity Index; BASFI: Bath AS Functional Index; NSAIDs: Non-steroidal anti-inflammatory drugs; r-axSpA = radiographic axial spondyloarthritis (axSpA); non-radiographic axSpA (nr-axSpA); NRS = numerical rating scale

Supporting image 2

*variables are mean ± standard deviation if not otherwise indicated; LS: Lumbar spine, CS: cervical spine; BASMI: Bath Ankylosing Spondylitis Metrology Index, ASPI: Ankylosing Spondylitis Performance-based Improvement, SPPB: Short Physical Performance Battery

Supporting image 3

*variables are mean ± standard deviation if not otherwise indicated; Diff: Difference
ROM: Range of motion in angular degrees/second;
ROK: range of kinematics in angular degrees/second;


Disclosures: D. Kiefer, Novartis, AbbVie/Abbott, Boehringer-Ingelheim, Janssen, UCB, Pfizer; J. Braun, None; L. Schneider, None; N. Kolle, None; U. Kiltz, AbbVie, Amgen, Biogen, Fresenius, GSK, Hexal, Novartis, Pfizer, Biocad, Lilly, Grünenthal, Janssen, MSD, Roche, UCB; I. Andreica, None; P. Sewerin, None; B. Buehring, AbbVie/Abbott, Gilead/Galapagos, Merck/MSD, Amgen, UCB, Biogen, Sanofi Genzyme, Theramex; s. herbold, None; X. Baraliakos, AbbVie, Lilly, Galapagos, MSD, Novartis, Pfizer, UCB, Bristol-Myers Squibb, Janssen, Roche, Sandoz, Sanofi.

To cite this abstract in AMA style:

Kiefer D, Braun J, Schneider L, Kolle N, Kiltz U, Andreica I, Sewerin P, Buehring B, herbold s, Baraliakos X. Clinically Relevant Differences in the Mobility of Patients with Axial Spondyloarthritis Related to Daytime of Performance [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/clinically-relevant-differences-in-the-mobility-of-patients-with-axial-spondyloarthritis-related-to-daytime-of-performance/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinically-relevant-differences-in-the-mobility-of-patients-with-axial-spondyloarthritis-related-to-daytime-of-performance/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology